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Abstract: 
 
Background: Peripheral blood basophils from 10% to 20% of donors fail to degranulate in 
response to cross-linking the high-affinity IgE receptor FcϵRI. The molecular mechanisms 
underlying the nonreleaser phenotype have not been established. Objectives: Our aim was to 
compare the expression of FcϵRI-associated protein tyrosine kinases between nonreleaser and 
releaser basophils. Methods: With use of Western blotting we investigated Syk and Lyn 
protein levels in highly purified basophils from 3 anti-IgE nonreleasers and 2 releasers. Results: 
We identified 3 healthy nonatopic donors whose nonreleaser basophils express FcϵRI normally 
but fail to express protein for the tyrosine kinase Syk, which is implicated in the initiation of 
FcϵRI-mediated secretion. Protein levels for the tyrosine kinase Lyn are somewhat reduced but 
not absent in nonreleaser basophils. Levels of Lyn and Syk protein are similar in B cells, 
eosinophils, and neutrophilsfrom releaser and nonreleaser donors. During these studies one 
nonreleaser “converted” into a releaser with concomitant basophil Syk expression. Conclusion: 
The absence of detectable Syk could explain the nonreleaser phenotype of basophils from some 
donors. 
 
Keywords: Basophils | signal transduction | nonreleaser | tyrosine kinase | Lyn | Syk | human 
 
Article: 
 
Abbreviations 
FcϵRI:  High-affinity receptor for IgE 
fMet peptide:  N-formyl-methionyl-leucyl-phenylalanine 
PMA:  Phorbol myristate acetate 
 
Cross-linking the high-affinity IgE receptor (FcϵRI) on mast cells and basophils initiates the 
release of mediators involved in allergic inflammation.1 Details of the signaling pathway have 
been established primarily in the RBL-2H3 mast cell model and in mouse bone marrow–derived 
mast cells. In these cells FcϵRI cross-linking sequentially activates 2 protein tyrosine kinases, 
Lyn, which principally phosphorylates the immunoreceptor tyrosine-based activation motif–
containing β and γ subunits of the FcϵRI, and Syk, which binds the phosphorylated receptor and 
in turn recruits and phosphorylates additional kinases, adaptor proteins, and enzymes, including 
phospholipase Cγ isoforms. These early events in turn stimulate Ca++ mobilization, guanosine 
triphosphatase activation, and the activation of multiple downstream enzymes, including protein 
kinase C isoforms and Erk and Jnk mitogen-activated protein kinase family members, resulting 
in secretion.2 
 
We showed recently that cross-linking the FcϵRI on human basophils activates the protein 
tyrosine kinases Lyn, Syk, and Zap70, and the resulting tyrosine phosphorylation of multiple 
cellular substrates is essential for FcϵRI-mediated basophil degranulation.3 Others have reported 
the wide variability in the secretory response of human basophils to anti-IgE antibody and, in 
particular, have established that basophils from 10% to 20% of donors do not release histamine 
in response to FcϵRI cross-linking.4, 5 
 
Here we identify 3 donors with nonreleaser basophils. These basophils fail to express Syk and 
have normal to lower levels of Lyn. B cells, eosinophils, and neutrophils from these donors have 
normal Syk and Lyn levels. Understanding the basophil-specific regulation of Lyn and Syk 
expression could yield new therapies for allergic inflammation. 
 
MATERIAL AND METHODS 
 
Reagents 
 
Antibodies to Lyn and Syk were from Santa Cruz Biotechnology, Santa Cruz, Calif. Affinity-
purified goat antihuman IgE antibody was from Biosource, Camarillo, Calif. Antibody 29C6 to 
the FcϵRI-α chain was a generous gift from Dr J. Kochan, Hoffman LaRoche. Calcium 
ionophore A23187, N-formyl-methionyl-leucyl-phenylalanine (fMet peptide), phorbol myristate 
acetate (PMA), Iscove’s medium, antibodies specific for leukocyte subsets and erythrocytes (CD 
antibodies and antiglycophorin), FITC-CD16, and antiactin were from Sigma, St Louis, Mo. 
 
Isolation of peripheral blood cells 
 
Basophil-enriched cell populations were isolated by Percoll gradient centrifugation and either 
used directly (at 25% to 60% purity for degranulation assays) or further purified to >99% 
basophils by sequential negative and positive selection and flow sorting, as described 
elsewhere.3, 6 
 
Isolation of other leukocytes 
 
To isolate B cells, the monocyte-lymphocyte fraction obtained after Percoll-gradient 
centrifugation was washed twice with PBS–bovine serum albumin followed by sequential 
incubation for 30 minutes at 4°C with mouse antibodies to CD19 and CD22 and with FITC-goat 
antimouse IgG antibody. FITC-positive B cells were isolated with use of an EPICS Elite cell 
sorter. Eosinophils and neutrophils in the granulocyte fraction from these gradients were 
separated by incubation with FITC-conjugated CD16 mAb and flow sorting into the CD16-
positive neutrophils and the CD16-negative eosinophils. Wright’s stain analysis confirmed that 
these preparations were >98% neutrophils or eosinophils. 
 
Histamine release and measurement 
 
Percoll-enriched basophils (1 × 105 cells per assay) were activated as described previously3 with 
the addition of anti-IgE (0.01-10 μg/mL), A23187 (500 ng/mL), fMet peptide (10–7 mol/L), or 
PMA (50 ng/mL). Total histamine content and fractional histamine release were measured with 
an RIA (ALPCO, Windham, NH). 
 
Western blotting for Lyn and Syk protein 
 
Highly purified basophils, B cells, eosinophils, and neutrophils were solubilized, and equal 
amounts of protein (10-25 μg/lane) or equal numbers of cell equivalents (0.6-2.5 × 105 cells/lane) 
were separated by SDS-PAGE and transferred to nitrocellulose. Western blotting with 1 μg/mL 
of antibodies to Lyn, Syk, and actin or with normal rabbit serum as a negative control (1:500 
dilution) was performed as described previously.3 Membranes were developed with use of the 
ultrasensitive enhanced chemiluminescence detection reagents (ECL, Amersham). 
 
RESULTS 
 
In multiple assays of FcϵRI-induced secretion basophils from 3 of 37 (8%) healthy blood donors 
consistently failed to degranulate in response to anti-IgE antibody. These donors, made up of a 
46-year-old man, his 16-year-old son, and a 31-year-old male, were taking no medications and 
had no history of symptomatic allergy or asthma. The first two patients had positive skin tests to 
one or more of a panel of common allergens during the time of these studies, indicating that their 
mast cell IgE-mediated pathways were probably intact. The third patient had a negative skin test 
result. 
 
Nonreleaser and releaser basophils contain similar amounts of histamine (Fig 1, A ). 
 
As previously reported,5 releaser basophils secrete optimally in response to between 0.1 and 1 
μg/mL concentrations of anti-IgE (Fig 1, A ). IgE-primed nonreleaser basophils showed no 
degranulation over a range of cross-linker concentrations from 0.01 to 10 μg/mL anti-IgE (Fig 
1, A ). 
 
Although FcϵRI-induced secretion was absent, nonreleaser basophils secreted normally when 
challenged with fMet peptide, which activates the G protein–coupled chemoattractant receptor, 
and with Ca++ ionophore and phorbol ester, which are thought to induce secretion in part by 
direct effects on cytoplasmic Ca++ levels and protein kinase C activity. These and similar results 
published previously4, 5 indicate that the nonreleaser phenotype results from the failure of early 
events in the FcϵRI signaling cascade. Consistent with the earlier reports, the expression of cell 
surface FcϵRI, measured by flow cytometry in cells labeled with mouse anti-FcϵRI mAb 
followed by FITC–anti-mouse IgG, was in the normal range (data not shown). 
 
 
Fig. 1. A, Specific impairment of FcϵRI-dependent degranulation in nonreleaser basophils. Percoll-enriched 
nonreleaser and releaser basophils were challenged with different concentrations of anti-IgE, other non-IgE-
mediated stimuli (A23187, fMet, or PMA), or with no stimulus (spon) for 30 minutes and assayed for degranulation. 
Data are results of 3 separate experiments for each donor, each done in duplicate (±SEM, n = 3). Numbers in 
parentheses indicate total histamine per 106 basophils for each donor from 2 separate experiments (±SEM; n = 
2) B, Nonreleaser basophils lack protein tyrosine kinase Syk. Lysates of highly purified (>99% pure) releaser and 
nonreleaser basophils (Bas), as well as B cells, eosinophils (eos), and neutrophils (neut) from same donors, were 
analyzed by Western blotting for Lyn, Syk, and actin protein expression. Upper panel, Equal amounts of protein (13 
μg/lane) were added to gel; lower panel (nonreleasers 2 and 3), equal numbers of cell equivalents were added to gel 
(2 × 105 cell equivalents/lane). Results are representative of 3 separate experiments for each donor. 
 
FcϵRI-mediated degranulation in human basophils involves the early activation of protein 
tyrosine kinases, particularly Lyn and Syk.3 We therefore compared levels of these 2 kinases 
between releaser and nonreleaser basophils. Kinase protein and messenger RNA levels were also 
analyzed in B cells, eosinophils, and neutrophils from the same donors. 
 
 
Fig. 2. A, Conversion of nonreleasing basophils to releasing basophils with concomitant Syk protein expression. 
Percoll-enriched basophils from nonreleaser 3 (tested approximately 1 month from the third of 3 experiments 
reported in Fig 1, A ) were challenged with different concentrations of anti-IgE, other non-IgE-mediated stimuli 
(A23187 or PMA), or no stimulus (spon)for 30 minutes and assayed for histamine release. Data are results of 2 
separate experiments, each performed in duplicate (±SEM, n = 2). B, Lysates of highly purified (>99% pure) 
nonreleaser basophils (Bas) from preparation used for fifth secretion analysis, as well as B cells, 
eosinophils (Eos), and neutrophils (Neut) from the same donor, were analyzed by Western blotting for Lyn, Syk, and 
actin protein expression. Equal numbers of cell equivalents were added to gel (2.6 × 105 cell equivalents/lane). 
Results are representative of 2 separate experiments. 
 
In the experiments illustrated in Fig 1, B, solubilized cell proteins were separated by SDS-PAGE 
and Western blots probed with antibodies to Lyn or Syk. Highly purified nonreleaser basophils 
contain the Src-related tyrosine kinase Lyn at lower levels than releaser basophils. Lyn levels 
were similar among B cells, eosinophils, and neutrophils from all donors regardless of the 
releaser or nonreleaser status of their basophils. Importantly, Syk protein was consistently 
undetectable in nonreleaser basophils. In contrast, Syk levels were similar among B cells, 
eosinophils, and neutrophils from donors with releaser and nonreleaser basophils. In contrast 
with Syk, Zap-70, previously detected at low levels in releaser basophils,3 was detectable in 
highly purified preparations of nonreleaser basophils (data not shown). 
 
Assays for kinase messenger RNA expression showed that both releaser and nonreleaser 
basophils contained messenger RNA for Lyn. Syk and Lyn were consistently detected in the 
monocyte-lymphocyte population from both releaser and nonreleaser donors. We were able to 
detect Syk message in 2 of 4 experiments for nonreleaser 1, 0 of 2 experiments for nonreleaser 2, 
and 3 of 3 experiments for nonreleaser 3 (data not shown). 
 
Remarkably, we detected anti-IgE-induced histamine release from basophils obtained from 
nonreleaser 3 in the last 2 of 5 experiments (Fig 2, B ). 
 
Western blotting performed at the time of the nonreleaser “converting” into a releaser revealed 
the presence of Lyn and Syk protein in the basophils at levels similar to those found in releaser 
basophils (Fig 2, B ). There were no obvious changes in levels of Lyn and Syk in B cells, 
neutrophils, and eosinophils before or after conversion of the basophils to the responder 
phenotype. 
 
DISCUSSION 
 
It has been known since 1973 that basophils from as many as 10% to 20% of nonatopic donors 
fail to secrete in response to FcϵRI cross-linking.7 This phenotype was found with somewhat 
lower frequency (3/37 or approximately 8%) among our donors (approximately 50% men and 
50% women, age range 16-50 years, approximately 25% Hispanic and 75% non-Hispanic white, 
all nonallergic by self-report). Mechanistic studies have so far not explained this phenotype. 
Nonreleaser basophils express the FcϵRI α subunit in the normal range, and donors do not show 
altered serum IgE levels.5, 8 In addition, studies of receptor composition demonstrated normal 
expression of the β subunit in nonreleaser basophils and showed additionally that the α, β, and γ 
subunits of nonreleaser FcϵRI have no primary structural changes.8, 9 Other explanations for the 
nonreleaser phenotype have been explored. Antibodies to the cell membrane phosphatase CD45 
can down-regulate Ca++ mobilization and histamine release in human basophils.10 However, flow 
cytometric experiments demonstrated no difference in CD45 expression between releaser and 
nonreleaser basophils.11 
 
We have established that nonreleaser basophils from 3 healthy donors lack the tyrosine kinase 
Syk and express normal-to-reduced levels of the protein tyrosine kinase Lyn. We hypothesize 
that Syk deficiencies account, at least in part, for the lack of FcϵRI-induced secretion. In contrast, 
small amounts of Zap70 were detectable in both releaser and nonreleaser basophils. These results 
demonstrate that Zap70 cannot substitute for Syk in the FcϵR1 signaling pathway leading to 
degranulation. Its function in human basophil signaling remains to be determined. 
 
Remarkably, Syk and Lyn appear to be expressed normally in B cells, eosinophils, and 
neutrophils from nonreleaser donors, suggesting that kinase expression may be regulated 
separately in basophils in comparison with other leukocytes. Because 2 of the 3 nonreleasers had 
positive skin test results to common antigens, we suppose that mast cell Syk is probably also 
expressed in adequate levels. 
 
The mechanism(s) underlying the absence of Syk from nonreleaser basophils is not yet known. 
Reduced Syk gene transcription, perhaps related to a mutation in the Syk promoter region or to 
fluctuation levels of basophil-specific transciptional activators (or repressors) and reduced Syk 
messenger RNA stability are both possible. Syk protein is particularly susceptible to cleavage 
from the full-length 72-kd form to a 40-kd form12and it is possible that mutations or 
modifications that selectively affect Syk itself or a Syk binding partner such as Cbl13 or 
tubulin14 may also contribute to the consistent absence of Syk protein from nonreleaser 
basophils. The recent discovery of an acridone-related Syk inhibitor that blocks FcϵRI-coupled 
Syk activation without affecting B-cell Syk activation15 supports the occurrence of cell type–
specific Syk-protein interactions that might affect Syk stability. The demonstration by 
Yamaguchi et al8 that 4 days in culture with IL-3 causes a partial recovery of secretion in 
nonreleaser basophils, and our observation that this recovery is accompanied by increased Lyn 
and Syk expression (data not shown) provides a system to explore events regulating the 
transcription or translation of basophil kinases. 
 
 
Fig. 3. Model for FcϵRI-mediated activation of releaser basophils (left) and for absence of FcϵRI-mediated 
activation in nonreleaser basophils (right). This schematic links basophil-specific absence of Syk to nonreleaser 
phenotype and indicates that fluctuation between Syk and Syk+ phenotype is possible in vivo. Future treatments for 
allergic inflammation may include drugs that target basophil-specific kinase expression. 
 
In the course of the current studies (approximately 1 year), we were never able to detect Syk 
protein in basophils from nonreleasers 1 and 2 and were never able to demonstrate FcϵRI-
mediated secretion in these cells. In the fourth and fifth experiments examining nonreleaser 3 we 
did detect anti-IgE-induced histamine release and concomitant basophil Syk expression. These 
data support anecdotal evidence that basophils from individual donors can cycle in and out of 
responsiveness over time. They provide further evidence that the expression of Syk protein is the 
critical component missing from nonreleaser basophils. 
 
The scheme in Fig 3 summarizes and interprets our results. 
 
In releaser basophils (left panel), previous work2, 3 indicates that FcϵRI cross-linking activates 
Lyn, leading to the phosphorylation of immunoreceptor tyrosine-based activation mofifs in the 
FcϵRI β and γ subunit cytoplasmic tails. Syk in turn is recruited via its tandem SH2 domains to 
the γ subunit phosphoimmunoreceptor tyrosine based activation motifs and activated. The 
subsequent Syk-mediated phosphorylation of target proteins is the critical event leading to signal 
propagation and physiologic responses, including secretion. In nonreleaser basophils (right 
panel), the sequence of events leading to signal propagation is blocked by the absence of Syk and 
no secretion occurs. We indicate that Syk expression is controlled by basophil-specific factors 
(because Syk-deficient basophils can coexist with Syk-containing B cells, eosinophils, and 
neutrophils) and that basophils are capable of fluctuating between the 2 phenotypes (because one 
donor changed from the nonreleaser to the releaser phenotype, with concomitant basophil Syk 
expression, during our studies). The evidence for basophil-specific kinase regulation raises the 
exciting possibility of developing new treatments for allergic inflammation based on drugs that 
target basophil-specific kinase expression. 
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